baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. CALL 03/25 22UA/ DE000HD8RVM5 /

2024-10-31 7:40:16 PM	Chg.0.0000	Bid8:59:54 PM	Ask8:59:54 PM	Underlying	Strike price	Expiration date	Option type
0.1200EUR	0.00%	- Bid Size: 45,000	- Ask Size: 45,000	BioNTech SE	180.00 USD	2025-03-19	Call

GlobeNewswire 08-29 Advanced Medical Balloons appoints top-performing US life-science executive to drive business growth

GlobeNewswire 08-29 Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform

TeleTrader 08-22 FDA okays Moderna, Pfizer updated vaccines

GlobeNewswire 08-22 Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vacc...

GlobeNewswire 08-16 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...

GlobeNewswire 08-14 Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire 08-08 Genmab Announces Financial Results for the First Half of 2024

GlobeNewswire 08-08 Genmab Updates 2024 Financial Guidance

TeleTrader 08-05 BioNTech posts revenue at €128.7 billion in Q2

GlobeNewswire 08-05 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 08-05 Genmab Takes Full Control of Acasunlimab Development Program

GlobeNewswire 08-01 Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 07-30 BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patie...

GlobeNewswire 07-22 BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024

GlobeNewswire 06-27 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...

GlobeNewswire 06-24 BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT...

GlobeNewswire 06-01 Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...

GlobeNewswire 05-29 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

GlobeNewswire 05-28 Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology ...

GlobeNewswire 05-21 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...

GlobeNewswire 05-21 Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announ...

GlobeNewswire 05-17 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

GlobeNewswire 05-17 Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

GlobeNewswire 05-09 Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

TeleTrader 05-06 BioNTech's Q1 revenue slumps 85% to €187.6M

UC WAR. CALL 03/25 22UA/ DE000HD8RVM5 /

If you wish to receive reply to your feedback, please provide your email address.